Prerequisites and limitations of the use of oral anticoagulants in pregnant women in real-world clinical practice

Relevance. Anticoagulants are commonly used during pregnancy is a fairly common practice. Due to the widespread use of oral anticoagulants in real practice and the high frequency of unplanned pregnancy, physicians should assess the risks and plan pregnancy management strategies.Objective. The purpos...

Full description

Saved in:
Bibliographic Details
Main Authors: Kh. A. Zagorodnikova, O. A. Bettikher, I. Ye. Zazerskaya
Format: Article
Language:Russian
Published: Publishing House OKI 2025-01-01
Series:Реальная клиническая практика: данные и доказательства
Subjects:
Online Access:https://www.myrwd.ru/jour/article/view/81
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1839591660447596544
author Kh. A. Zagorodnikova
O. A. Bettikher
I. Ye. Zazerskaya
author_facet Kh. A. Zagorodnikova
O. A. Bettikher
I. Ye. Zazerskaya
author_sort Kh. A. Zagorodnikova
collection DOAJ
description Relevance. Anticoagulants are commonly used during pregnancy is a fairly common practice. Due to the widespread use of oral anticoagulants in real practice and the high frequency of unplanned pregnancy, physicians should assess the risks and plan pregnancy management strategies.Objective. The purpose of this analysis was to assess the legal background and evidence on the risks associated with the use of oral anticoagulants in pregnant women in real-world clinical practice.Materials and methods. An analysis of the official instructions for the use of oral anticoagulants registered in Russia, an analysis of the published literature on reproductive toxicity and the use of drugs during pregnancy, and a general comparative analysis of the predominance of individual oral anticoagulants in practical healthcare in Russia.Results. The results of the analysis revealed high variability in the restrictions on the use of oral anticoagulants during pregnancy. At the same time, the actual evidence of reproductive toxicity for drugs does not differ significantly and indicates the absence of signals of potential teratogenicity, at least based on the available number of observations. The maximum number of pregnancy observations exceeding the number of observations on warfarin use was reported for the use of rivaroxaban (505 cases in the largest analysis). The remaining representatives are described by several dozen observations. In Russia, the use of oral anticoagulants is also a prerequisite for the more likely use of rivaroxaban and apixaban in cases of unplanned pregnancy.Conclusions. In real-world clinical practice, exposure to oral anticoagulants is a prerequisite for pregnancy, which requires decision-making on strategies for pregnancy management. Instructions for the use of drugs do not contain reasonable information or formulations for decision-making based on accumulated knowledge about reproductive toxicity. Based on published data on the use of drugs in this group during pregnancy in real-world clinical practice, there is no sign of teratogenic potential for all representatives, with the exception of warfarin, whereas the largest number of observations concerns the most commonly used rivaroxaban.
format Article
id doaj-art-225e796710c94dc8a064e9a60c6c1adf
institution Matheson Library
issn 2782-3784
language Russian
publishDate 2025-01-01
publisher Publishing House OKI
record_format Article
series Реальная клиническая практика: данные и доказательства
spelling doaj-art-225e796710c94dc8a064e9a60c6c1adf2025-08-03T13:00:11ZrusPublishing House OKIРеальная клиническая практика: данные и доказательства2782-37842025-01-0144192710.37489/2782-3784-myrwd-05970Prerequisites and limitations of the use of oral anticoagulants in pregnant women in real-world clinical practiceKh. A. Zagorodnikova0O. A. Bettikher1I. Ye. Zazerskaya2Almazov National Medical Research CentreAlmazov National Medical Research CentreAlmazov National Medical Research CentreRelevance. Anticoagulants are commonly used during pregnancy is a fairly common practice. Due to the widespread use of oral anticoagulants in real practice and the high frequency of unplanned pregnancy, physicians should assess the risks and plan pregnancy management strategies.Objective. The purpose of this analysis was to assess the legal background and evidence on the risks associated with the use of oral anticoagulants in pregnant women in real-world clinical practice.Materials and methods. An analysis of the official instructions for the use of oral anticoagulants registered in Russia, an analysis of the published literature on reproductive toxicity and the use of drugs during pregnancy, and a general comparative analysis of the predominance of individual oral anticoagulants in practical healthcare in Russia.Results. The results of the analysis revealed high variability in the restrictions on the use of oral anticoagulants during pregnancy. At the same time, the actual evidence of reproductive toxicity for drugs does not differ significantly and indicates the absence of signals of potential teratogenicity, at least based on the available number of observations. The maximum number of pregnancy observations exceeding the number of observations on warfarin use was reported for the use of rivaroxaban (505 cases in the largest analysis). The remaining representatives are described by several dozen observations. In Russia, the use of oral anticoagulants is also a prerequisite for the more likely use of rivaroxaban and apixaban in cases of unplanned pregnancy.Conclusions. In real-world clinical practice, exposure to oral anticoagulants is a prerequisite for pregnancy, which requires decision-making on strategies for pregnancy management. Instructions for the use of drugs do not contain reasonable information or formulations for decision-making based on accumulated knowledge about reproductive toxicity. Based on published data on the use of drugs in this group during pregnancy in real-world clinical practice, there is no sign of teratogenic potential for all representatives, with the exception of warfarin, whereas the largest number of observations concerns the most commonly used rivaroxaban.https://www.myrwd.ru/jour/article/view/81warfarinrivaroxabandabigatranapixabanedoxabanpregnancyreproductive toxicityteratogenicityreal-world clinical practice
spellingShingle Kh. A. Zagorodnikova
O. A. Bettikher
I. Ye. Zazerskaya
Prerequisites and limitations of the use of oral anticoagulants in pregnant women in real-world clinical practice
Реальная клиническая практика: данные и доказательства
warfarin
rivaroxaban
dabigatran
apixaban
edoxaban
pregnancy
reproductive toxicity
teratogenicity
real-world clinical practice
title Prerequisites and limitations of the use of oral anticoagulants in pregnant women in real-world clinical practice
title_full Prerequisites and limitations of the use of oral anticoagulants in pregnant women in real-world clinical practice
title_fullStr Prerequisites and limitations of the use of oral anticoagulants in pregnant women in real-world clinical practice
title_full_unstemmed Prerequisites and limitations of the use of oral anticoagulants in pregnant women in real-world clinical practice
title_short Prerequisites and limitations of the use of oral anticoagulants in pregnant women in real-world clinical practice
title_sort prerequisites and limitations of the use of oral anticoagulants in pregnant women in real world clinical practice
topic warfarin
rivaroxaban
dabigatran
apixaban
edoxaban
pregnancy
reproductive toxicity
teratogenicity
real-world clinical practice
url https://www.myrwd.ru/jour/article/view/81
work_keys_str_mv AT khazagorodnikova prerequisitesandlimitationsoftheuseoforalanticoagulantsinpregnantwomeninrealworldclinicalpractice
AT oabettikher prerequisitesandlimitationsoftheuseoforalanticoagulantsinpregnantwomeninrealworldclinicalpractice
AT iyezazerskaya prerequisitesandlimitationsoftheuseoforalanticoagulantsinpregnantwomeninrealworldclinicalpractice